MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 203071 | Name: UNBS5162
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. In vivo UNBS5162 after repeat administration significantly increased survival in orthotopic human prostate cancer models. Results obtained by the National Cancer Institute (NCI) using UNBS3157 and UNBS5162 against the NCI 60 cell line panel did not show a correlation with any other compound present in the NCI database, including amonafide, thereby suggesting a unique mechanism of action for these two novel naphthalimides.

Chemical Structure

UNBS5162
UNBS5162
CAS#956590-23-1

Theoretical Analysis

MedKoo Cat#: 203071

Name: UNBS5162

CAS#: 956590-23-1

Chemical Formula: C17H18N4O3

Exact Mass: 326.1379

Molecular Weight: 326.35

Elemental Analysis: C, 62.57; H, 5.56; N, 17.17; O, 14.71

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,650.00 Ready to ship
1g USD 4,250.00 Ready to ship
2g USD 6,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
UNBS-5162, UNBS 5162, UNBS5162
IUPAC/Chemical Name
1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea
InChi Key
WCKZRLOUKYFJDY-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H18N4O3/c1-20(2)6-7-21-15(22)12-5-3-4-10-8-11(19-17(18)24)9-13(14(10)12)16(21)23/h3-5,8-9H,6-7H2,1-2H3,(H3,18,19,24)
SMILES Code
O=C(N)NC1=CC2=CC=CC(C(N(CCN(C)C)C3=O)=O)=C2C3=C1
Appearance
Yellow solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The MTD or dose-limiting toxicity for UNBS5162 was not reached due to the magnitude of QTc prolongation at the highest dose of 234 mg/m(2)/week that led to study termination. ( Int J Clin Oncol. 2013 Oct;18(5):934-41.)
Biological target:
UNBS5162 is a pan-antagonist of CXCL chemokine expression.
In vitro activity:
The effect of UNBS5162 on cell proliferation, mobility and apoptosis in HCT116 cells was investigated, and the underlying mechanism was explored. A CCK8 assay revealed that UNBS5162 can block the proliferation of colon cancer cells. Cell migration and invasion ability of HCT116 cells were inhibited by UNBS5162. In addition, Annexin V-FITC/PI assay and Western blot analysis were performed to detect whether UNBS5162 could induce cell apoptosis. The results indicated that UNBS5162 increases the number of apoptotic cells remarkably. Furthermore, Western blot analysis demonstrated that UNBS5162 down-regulates the expression level of Bcl2, and up-regulates that of Bax as well as the level of activated Caspase-3. Moreover, UNBS5162 substantially inhibited the phosphorylation of Akt and its downstream effector mTOR, and reduced the expression of p-70. Taken together, these results suggest that UNBS5162 should be considered as a potent therapeutic anticancer agent that targets the PI3K/AKT signaling pathway. Reference: Med Sci (Paris). 2018 Oct;34 Focus issue F1:99-104. https://www.medecinesciences.org/en/articles/medsci/full_html/2018/09/medsci180278s/medsci180278s.html
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMF 3.0 9.19
DMF:PBS (pH 7.2) (1:1) 0.5 1.53
DMSO 19.3 58.99
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 326.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhang F, Lv HZ, Liu JM, Ye XY, Wang CC. UNBS5162 inhibits colon cancer growth via suppression of PI3K/Akt signaling pathway. Med Sci (Paris). 2018 Oct;34 Focus issue F1:99-104. doi: 10.1051/medsci/201834f117. Epub 2018 Nov 7. PMID: 30403183. 2. Liu C, Xing J, Gao Y. UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis. Thorac Cancer. 2018 Jan;9(1):105-111. doi: 10.1111/1759-7714.12546. Epub 2017 Nov 11. PMID: 29130641; PMCID: PMC5754305.
In vitro protocol:
1. Zhang F, Lv HZ, Liu JM, Ye XY, Wang CC. UNBS5162 inhibits colon cancer growth via suppression of PI3K/Akt signaling pathway. Med Sci (Paris). 2018 Oct;34 Focus issue F1:99-104. doi: 10.1051/medsci/201834f117. Epub 2018 Nov 7. PMID: 30403183. 2. Liu C, Xing J, Gao Y. UNBS5162 inhibits the proliferation of human A549 non-small-cell lung cancer cells by promoting apoptosis. Thorac Cancer. 2018 Jan;9(1):105-111. doi: 10.1111/1759-7714.12546. Epub 2017 Nov 11. PMID: 29130641; PMCID: PMC5754305.
In vivo protocol:
TBD
1: Wang X, Zhang M, Xu J, Li X, Xiong J, Cao H, Dou F, Zhai X, Sun H. A novel approach for target deconvolution from phenotype-based screening using knowledge graph. Sci Rep. 2025 Jan 18;15(1):2414. doi: 10.1038/s41598-025-86166-w. PMID: 39827292; PMCID: PMC11742725. 2: Li HH, Song XX, Liu B, Yang WP. UNBS5162 as a novel naphthalimide holds efficacy in human gastric carcinoma cell behaviors mediated by AKT/ERK signaling pathway. Drug Dev Ind Pharm. 2019 Aug;45(8):1306-1312. doi: 10.1080/03639045.2019.1607870. Epub 2019 May 24. PMID: 30995142. 3: Ye Y, Huang S, Wu Y. UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway. Cancer Manag Res. 2019 Mar 22;11:2339-2348. doi: 10.2147/CMAR.S177623. PMID: 30962721; PMCID: PMC6434921. 4: Wang Q, Shi W. UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway. Oncol Lett. 2019 Mar;17(3):2976-2982. doi: 10.3892/ol.2019.9890. Epub 2019 Jan 4. PMID: 30854075; PMCID: PMC6365959. 5: Zhang F, Lv HZ, Liu JM, Ye XY, Wang CC. UNBS5162 inhibits colon cancer growth via suppression of PI3K/Akt signaling pathway. Med Sci (Paris). 2018 Oct;34 Focus issue F1:99-104. doi: 10.1051/medsci/201834f117. Epub 2018 Nov 7. PMID: 30403183. 6: Yue X, Li M, Chen D, Xu Z, Sun S. UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cells. Exp Ther Med. 2018 Nov;16(5):3921-3928. doi: 10.3892/etm.2018.6675. Epub 2018 Sep 3. PMID: 30344670; PMCID: PMC6176139. 7: Shi X, Yang L, Xie J, Zhao Y, Cong J, Li Z, Li H, Cheng X, Fan J. UNBS5162 inhibits proliferation of human melanoma cells by inducing apoptosis via the PI3K/Akt pathway. Mol Med Rep. 2018 Sep;18(3):3382-3388. doi: 10.3892/mmr.2018.9321. Epub 2018 Jul 25. PMID: 30066877. 8: Wang B, Shen J, Wang J. UNBS5162 inhibits proliferation of human retinoblastoma cells by promoting cell apoptosis. Onco Targets Ther. 2017 Nov 6;10:5303-5309. doi: 10.2147/OTT.S145518. PMID: 29158682; PMCID: PMC5683769. 9: Liu C, Xing J, Gao Y. UNBS5162 inhibits the proliferation of human A549 non- small-cell lung cancer cells by promoting apoptosis. Thorac Cancer. 2018 Jan;9(1):105-111. doi: 10.1111/1759-7714.12546. Epub 2017 Nov 11. PMID: 29130641; PMCID: PMC5754305. 10: He D, Zhang S. UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway. Mol Med Rep. 2018 Jan;17(1):549-555. doi: 10.3892/mmr.2017.7893. Epub 2017 Oct 26. PMID: 29115622. 11: Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R. Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 2013 Oct;18(5):934-41. doi: 10.1007/s10147-012-0475-8. Epub 2012 Oct 11. PMID: 23053399; PMCID: PMC6075731. 12: Mijatovic T, Mahieu T, Bruyère C, De Nève N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, Decaestecker C, Van Quaquebeke E, Darro F, Kiss R. UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 2008 Jun;10(6):573-86. doi: 10.1593/neo.08290. PMID: 18516294; PMCID: PMC2386542.